Optispring (Tetryzoline Hydrochloride)

Tetryzoline hydrochloride acts as a selective alpha‑adrenergic agonist. By stimulating alpha receptors on conjunctival blood‑vessel smooth muscle, it causes vasoconstriction, which reduces blood flow to the ocular surface and diminishes visible redness.

The appropriate dosing regimen for Optispring is determined by a qualified healthcare professional. Typically, one to two drops are instilled in the affected eye(s) no more than four times daily, but the prescriber’s instructions must be followed.

Safety data for tetryzoline hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using Optispring to weigh potential risks and benefits.

To request Optispring, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Optispring’s active ingredient, tetryzoline hydrochloride, offers rapid vasoconstriction similar to other imidazoline‑based decongestants such as naphazoline. Compared with older agents, tetryzoline often provides a slightly longer duration of redness relief, but all ocular decongestants share comparable safety profiles when used as directed.

Optispring should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from direct light and moisture, and keep the cap tightly closed to maintain sterility.

Optispring is applied topically to the eye. The user should wash hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. Close the eye gently for a few seconds to allow distribution.

Serious but rare risks include allergic conjunctivitis, corneal ulceration, and a significant rise in intraocular pressure that could worsen glaucoma. Any sudden vision changes, severe pain, or persistent redness should prompt immediate medical evaluation.

Optispring should be avoided by individuals with known hypersensitivity to tetryzoline or other imidazoline compounds, patients with narrow‑angle glaucoma, and those who have experienced severe ocular reactions to similar decongestants. Consultation with a healthcare provider is essential before use in these groups.